Basics Agios Pharmaceuticals, Inc. Agios Pharmaceuticals Inc is a biopharmaceutical company which focuses on developing treatments geared towards cancer and rare genetic disorders of metabolism. It also emphasizes on developing potentially transformative small-molecule medicines. IPO Date: July 24, 2013 Sector: Healthcare Industry: Biotech Market Cap: $2.04B Activated in VL: True Average Daily Range Avg Daily Range: $1.23 | 2.55% Avg Daily Range (30 D): $0.73 | 2.12% Avg Daily Range (90 D): $0.73 | 2.38% Institutional Daily Volume Avg Daily Volume: .52M Avg Daily Volume (30 D): .47M Avg Daily Volume (90 D): .47M Trade Size Avg Trade Size (Sh.): 75 Avg Trade Size (Sh.) (30 D): 48 Avg Trade Size (Sh.) (90 D): 48 Institutional Trades Total Inst.Trades: 5,674 Avg Inst. Trade: $2.35M Avg Inst. Trade (30 D): $2.82M Avg Inst. Trade (90 D): $2.7M Avg Inst. Trade Volume: .05M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $3.18M Avg Closing Trade (30 D): $3.78M Avg Closing Trade (90 D): $3.59M Avg Closing Volume: 76.76K     News Jun 26, 2025 @ 11:00 AM TRVI STOCKHOLDER ALERT: Kaskela Law LLC Announces ... Source: Kaskela Law Llc May 28, 2025 @ 11:00 AM Agios to Present at Goldman Sachs 46th Annual Glob... Source: N/A May 14, 2025 @ 2:00 PM Agios to Highlight Pyruvate Kinase Activation Port... Source: N/A May 9, 2025 @ 11:00 AM Agios to Present at the 2025 RBC Capital Markets G... Source: N/A May 2, 2025 @ 11:00 AM Agios to Present at the BofA Securities 2025 Healt... Source: N/A Financials   TTM Q1 2025 Q4 2024 Basic EPS $11.69 $-1.55 $-1.72 Diluted EPS $11.24 $-1.55 $-1.74 Revenue $ 37.04M $ 8.73M $ 10.73M Gross Profit $ 32.41M $ 7.64M $ 9.47M Net Income / Loss $ 665.99M $ -89.29M $ -96.52M Operating Income / Loss $ -440.29M $ -106.63M $ -125.04M Cost of Revenue $ 4.62M $ 1.09M $ 1.26M Net Cash Flow $ -39.8M $ 2.72M $ -177.48M PE Ratio 0.00